Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panic! No, don't panic! ECJ embryonic stem cells ruling divides opinion

This article was originally published in Scrip

Executive Summary

One set of interested parties has loudly bemoaned the European Court of Justice's ruling that embryonic stem cells cannot be patented, lamenting that it will stifle investment in research in the sector and lead to a shift in commercial development away from Europe. But another section of Europe's stem cell community has warned against such a reaction, arguing that paradoxically, the ruling could actually prove a net positive for the sector.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014887

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel